Beacita (Orlistat 60 mg)
Hard capsule containing orlistat — over-the-counter weight management aid
Quick Facts About Beacita
Key Takeaways About Beacita
- Fat absorption blocker: Beacita (orlistat 60 mg) prevents about 25% of dietary fat from being absorbed, helping you lose more weight than diet alone
- Over-the-counter availability: Available without a prescription for adults with a BMI of 28 or above who are committed to a lower-fat, reduced-calorie diet
- Take with meals: One capsule three times daily with each main meal containing fat — skip the dose if you skip a meal or eat a fat-free meal
- Supplement vitamins: Orlistat can reduce absorption of fat-soluble vitamins (A, D, E, K), so take a daily multivitamin at bedtime
- Diet matters: Gastrointestinal side effects are directly linked to dietary fat intake — following a lower-fat diet significantly reduces these effects
What Is Beacita and What Is It Used For?
Beacita contains orlistat 60 mg, a lipase inhibitor that blocks the digestion and absorption of approximately 25% of dietary fat. It is used together with a mildly reduced-calorie, lower-fat diet to help overweight adults (BMI ≥ 28) lose weight.
Beacita is a weight management medication that belongs to a class of drugs known as gastrointestinal lipase inhibitors. The active ingredient, orlistat, works locally in the digestive system rather than being absorbed into the bloodstream. When you take Beacita with a meal, orlistat attaches to the lipase enzymes in your stomach and small intestine, preventing them from breaking down approximately one quarter of the fat you have eaten. This undigested fat then passes through the body and is excreted naturally in the stool.
The European Medicines Agency (EMA) has approved orlistat 60 mg capsules for over-the-counter use in adults aged 18 years and older who are overweight, defined as having a body mass index (BMI) of 28 kg/m² or above. Beacita is not a standalone treatment for obesity; rather, it is designed to complement a comprehensive weight management programme that includes dietary modification and increased physical activity. Clinical trials have demonstrated that patients taking orlistat 60 mg three times daily in combination with a reduced-calorie diet lose approximately 50% more weight than those following the same diet with a placebo.
The medication has been extensively studied in large-scale randomised controlled trials involving thousands of participants. A landmark meta-analysis published in the Cochrane Database of Systematic Reviews found that orlistat consistently produces statistically significant weight loss compared to placebo across diverse patient populations. Importantly, orlistat has also been shown to improve cardiovascular risk factors, including reductions in total cholesterol, LDL cholesterol, blood pressure, and fasting blood glucose levels, independent of weight loss alone.
It is important to understand that Beacita is intended for gradual, sustained weight loss rather than rapid results. Most people can expect to lose between 1 and 2 additional pounds per month compared to dieting alone. The medication works best when used consistently as part of a long-term commitment to healthier eating habits. Studies show that patients who achieve early weight loss (at least 2 kg within the first 4 weeks) are more likely to achieve clinically meaningful weight loss over the full treatment period.
Beacita contains 60 mg of orlistat per capsule and is available without a prescription. The prescription-strength version (sold as Xenical in many countries) contains 120 mg of orlistat per capsule and blocks approximately one third of dietary fat. Both versions work through the same mechanism, but the OTC version has a lower dose and is suitable for self-management of weight loss under pharmacist guidance.
What Should You Know Before Taking Beacita?
Before starting Beacita, ensure your BMI is 28 or above, that you are not pregnant or breastfeeding, and that you inform your pharmacist about all other medications you take. Certain conditions and medications are contraindicated with orlistat use.
Contraindications
Do not take Beacita if you are allergic to orlistat or any of the other ingredients in the capsule. Additionally, Beacita should not be used in the following circumstances:
- Chronic malabsorption syndrome: If you have a condition that impairs your body's ability to absorb nutrients from food, orlistat could worsen nutritional deficiencies
- Cholestasis: Beacita is contraindicated in patients with reduced bile flow or biliary obstruction, as the medication's mechanism depends on normal fat digestion processes
- Concurrent ciclosporin use: If you are taking ciclosporin (an immunosuppressant), do not use Beacita, as orlistat can significantly reduce ciclosporin absorption and compromise transplant outcomes
- Concurrent warfarin or other anticoagulants: Patients on warfarin therapy should consult their doctor before using Beacita, as orlistat may alter anticoagulant effects
- Pregnancy and breastfeeding: Beacita has not been adequately studied in pregnant or breastfeeding women and should not be used during these periods
If you are currently taking any prescription medications, speak to your doctor or pharmacist before starting Beacita. This is particularly important for medications with narrow therapeutic windows, where even small changes in absorption could have significant clinical consequences. Orlistat does not directly interact with many drugs, but because it alters fat absorption, it can indirectly affect the uptake of certain fat-soluble medications.
Before starting Beacita, you should also consider whether your weight gain might have an underlying medical cause. Conditions such as hypothyroidism, Cushing's syndrome, and polycystic ovary syndrome can contribute to weight gain and may require specific medical treatment rather than orlistat therapy. If you have not had a recent medical check-up, consult your healthcare provider to rule out secondary causes of obesity before beginning self-treatment with Beacita.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Beacita if any of the following apply to you:
- Diabetes mellitus: If you have type 2 diabetes, orlistat may improve blood glucose control, which could require adjustments to your diabetes medication. Monitor your blood sugar more frequently when starting Beacita and consult your doctor about potential dose changes to insulin or oral hypoglycaemic agents
- Kidney disease: Rare cases of oxalate nephropathy (kidney damage from oxalate crystals) have been reported in patients taking orlistat. If you have existing kidney problems, discuss the risks with your healthcare provider before starting treatment
- Thyroid medication: If you take levothyroxine, be aware that orlistat may reduce its absorption. Take levothyroxine and Beacita at least 4 hours apart, and your doctor may need to monitor your thyroid function more closely
- Epilepsy medication: Orlistat may reduce the absorption of certain anti-epileptic drugs, potentially increasing the risk of seizures. If you take anti-epileptic medication, consult your neurologist before starting Beacita
- HIV treatment: Orlistat may reduce the effectiveness of antiretroviral medications. Patients on HIV therapy should not use Beacita without medical supervision
- Eating disorders: Beacita is not appropriate for individuals with anorexia nervosa, bulimia nervosa, or other eating disorders. It should only be used as part of a healthy, balanced approach to weight management
While taking Beacita, you should follow a nutritionally balanced, mildly reduced-calorie diet. Approximately 30% of your total daily calories should come from fat, and your fat intake should be spread evenly across three main meals. Eating a very high-fat meal while taking Beacita significantly increases the likelihood of gastrointestinal side effects. A useful guideline is to aim for no more than approximately 15 grams of fat per meal.
Pregnancy and Breastfeeding
Beacita should not be used during pregnancy. Weight loss during pregnancy is not recommended, as it may harm the developing foetus by restricting essential nutrient supply. If you discover that you are pregnant while taking Beacita, stop the medication immediately and consult your healthcare provider. There are no adequate clinical data on the use of orlistat in pregnant women, so the potential risk to the foetus is unknown.
Beacita should also not be used while breastfeeding. It is unknown whether orlistat passes into breast milk. Furthermore, reduced fat absorption could theoretically affect the nutritional quality of breast milk and, consequently, the infant's nutrition. If you are breastfeeding, discuss alternative weight management strategies with your healthcare provider.
Women of childbearing potential who are sexually active should use reliable contraception while taking Beacita. Note that Beacita may reduce the effectiveness of oral contraceptive pills if severe diarrhoea occurs. In such cases, an additional barrier method of contraception is recommended. If you experience severe or prolonged diarrhoea while taking Beacita and the oral contraceptive pill, consult your doctor about additional precautions.
Do not take Beacita if you are pregnant or breastfeeding. Weight loss during pregnancy can be harmful to the baby. If you become pregnant while taking Beacita, stop the medication immediately and contact your healthcare provider.
How Does Beacita Interact with Other Drugs?
Orlistat can affect the absorption of certain fat-soluble medications and vitamins. Key interactions include ciclosporin, warfarin, levothyroxine, amiodarone, anti-epileptic drugs, and antiretroviral medicines. Always inform your pharmacist about all medications you take.
Drug interactions with Beacita primarily result from its mechanism of action: by reducing fat absorption in the gastrointestinal tract, orlistat can also reduce the absorption of fat-soluble substances, including certain medications and vitamins. While orlistat has minimal systemic absorption (less than 1% of the dose reaches the bloodstream), its local effect on fat digestion can have clinically significant consequences for co-administered drugs.
The most important consideration is that orlistat reduces the absorption of fat-soluble vitamins A, D, E, and K. This effect is predictable and manageable: patients should take a daily multivitamin supplement containing these vitamins. The supplement should be taken at bedtime or at least 2 hours before or after the Beacita dose to prevent the orlistat from interfering with vitamin absorption from the supplement itself.
Beyond vitamins, several prescription medications require careful attention when used alongside Beacita. The interactions can range from minor (requiring monitoring) to major (requiring avoidance of concurrent use). The table below summarises the most clinically important drug interactions with orlistat.
Major Drug Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Ciclosporin | Reduced absorption | Significantly decreased ciclosporin blood levels; risk of transplant rejection | Contraindicated – do not use together |
| Warfarin / Anticoagulants | Altered vitamin K absorption | May increase INR and bleeding risk due to reduced vitamin K uptake | Monitor INR more frequently; consult prescriber |
| Levothyroxine | Reduced absorption | Hypothyroidism may worsen; TSH levels may rise | Take at least 4 hours apart; monitor thyroid function |
| Amiodarone | Reduced absorption | Decreased amiodarone plasma levels; risk of arrhythmia recurrence | Consult cardiologist before concurrent use |
| Anti-epileptic drugs (e.g., valproate, lamotrigine) | Reduced absorption | Risk of breakthrough seizures if drug levels fall | Consult neurologist; monitor drug levels |
| Antiretroviral medicines (HIV) | Reduced absorption | Risk of HIV treatment failure if drug levels drop | Avoid concurrent use without specialist oversight |
| Oral contraceptives | Reduced absorption (if diarrhoea occurs) | Potential contraceptive failure if severe diarrhoea develops | Use additional barrier method if diarrhoea occurs |
| Fat-soluble vitamins (A, D, E, K) | Reduced absorption | Risk of vitamin deficiency with prolonged use | Take multivitamin at bedtime or 2+ hours after dose |
The table above covers the most important known interactions, but it is not exhaustive. Always carry a complete list of all your medications and share it with your pharmacist before purchasing Beacita. If you are taking any prescription medication, it is wise to discuss Beacita use with your prescribing doctor, even if the medication is not listed above. New drug interaction data emerge regularly, and your healthcare provider can assess the most current evidence for your specific medication combination.
There is no known direct interaction between orlistat and alcohol. However, alcoholic beverages contribute calories without nutritional benefit, which can undermine your weight loss efforts. Additionally, some alcoholic drinks contain fat (e.g., cream-based cocktails), which could contribute to gastrointestinal side effects when combined with Beacita. Moderate alcohol consumption is generally acceptable, but discuss your specific situation with a healthcare provider.
What Is the Correct Dosage of Beacita?
The recommended dose is one 60 mg capsule three times daily, taken immediately before, during, or up to one hour after each main meal. Do not take more than three capsules per day. Skip the dose if you skip a meal or eat a fat-free meal.
The dosage of Beacita is straightforward: adults take one 60 mg hard capsule with each of their three main meals. The capsule should be swallowed whole with water. It can be taken immediately before starting the meal, at any point during the meal, or up to one hour after finishing the meal. If more than one hour has passed since you finished eating, there is no benefit in taking the capsule, as the lipase enzymes will have already digested most of the dietary fat.
Adults
Standard Adult Dosage
Take one Beacita 60 mg capsule three times daily with your three main meals. Each meal should be nutritionally balanced and contain approximately 15 grams of fat or less. Your total daily calorie intake should be mildly reduced (typically 500–600 calories below your daily energy requirement). Distribute your daily fat, carbohydrate, and protein intake roughly equally across the three meals.
If your meal contains no fat, you do not need to take the capsule. Taking Beacita with a fat-free meal will not provide any additional benefit and is unnecessary. Similarly, if you skip a meal entirely, skip the corresponding Beacita dose. Never take extra capsules to make up for missed doses.
Children and Adolescents
Paediatric Use
Beacita is not recommended for children and adolescents under 18 years of age. The safety and efficacy of orlistat 60 mg in paediatric populations have not been established in this OTC formulation. Weight management in children and adolescents requires a different approach, focusing primarily on behavioural and dietary interventions under the guidance of a paediatrician or specialist. If your child is overweight, consult a healthcare provider for appropriate advice.
Elderly Patients
Geriatric Dosage Considerations
There is limited clinical data on the use of Beacita in patients over 65 years of age. While no specific dose adjustment is required based on age alone, elderly patients are more likely to be taking multiple medications, which increases the potential for drug interactions. Older adults may also be at greater risk of nutrient deficiencies, particularly vitamin D and calcium, which could be exacerbated by orlistat use. Elderly patients should discuss the appropriateness of Beacita with their doctor or pharmacist before starting treatment.
Missed Dose
If you forget to take your Beacita capsule during or within one hour of a meal, simply skip that dose and take your next capsule with your next main meal as usual. Do not take a double dose to compensate for a missed one. Taking more orlistat than recommended does not increase fat blocking proportionally, but it does increase the risk of gastrointestinal side effects.
If you consistently forget doses, consider keeping your Beacita capsules near where you eat your meals as a visual reminder. Consistency is important for achieving the best results, but occasional missed doses will not significantly impact your overall weight loss trajectory, provided you maintain your reduced-calorie, lower-fat diet.
Overdose
If you accidentally take more Beacita capsules than recommended, contact your pharmacist, doctor, or local poison control centre for advice. In clinical studies, single doses of 800 mg orlistat and multiple doses of up to 400 mg three times daily for 15 days were studied in normal-weight and obese subjects without significant adverse findings. However, if a significant overdose occurs, the patient should be observed for 24 hours. Based on the available evidence, any systemic effects attributable to orlistat should be rapidly reversible.
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Adults (BMI ≥ 28) | 60 mg three times daily | Take with each main meal; follow a reduced-calorie, lower-fat diet |
| Elderly (≥65 years) | 60 mg three times daily | No dose adjustment needed; monitor for drug interactions and nutritional status |
| Children (<18 years) | Not recommended | Safety and efficacy not established in this age group |
| Renal impairment | 60 mg three times daily | Use with caution; rare reports of oxalate nephropathy |
| Hepatic impairment | 60 mg three times daily | No dose adjustment needed; minimal systemic absorption |
Do not use Beacita for longer than 6 months without consulting a healthcare provider. If you have not achieved meaningful weight loss (at least 5% of your initial body weight) after 12 weeks of consistent use combined with a reduced-calorie diet, discuss your options with a doctor or pharmacist. Beacita may not be the right approach for everyone, and a healthcare provider can help identify alternative strategies.
What Are the Side Effects of Beacita?
The most common side effects of Beacita are gastrointestinal, including oily stools, flatulence with discharge, urgent bowel movements, and oily spotting. These effects are directly related to dietary fat intake and are significantly reduced by following a lower-fat diet.
Side effects of Beacita are predominantly gastrointestinal and are a direct consequence of its mechanism of action. When orlistat blocks the digestion of dietary fat, the undigested fat passes through the intestines and is excreted in the stool. This leads to characteristic changes in bowel habits that many users experience, particularly in the early weeks of treatment or after eating meals that are higher in fat than recommended.
These gastrointestinal effects are not harmful and are, in a sense, a sign that the medication is working. However, they can be uncomfortable and socially inconvenient. The single most effective way to minimise these side effects is to adhere strictly to a lower-fat diet. Clinical data show that patients who keep their fat intake to around 15 grams per meal (approximately 45 grams per day total, or about 30% of a 1,500–calorie diet) experience significantly fewer gastrointestinal symptoms.
Most gastrointestinal side effects occur within the first few weeks of treatment and tend to decrease as patients learn to manage their fat intake. In clinical trials, the majority of gastrointestinal events were classified as mild and did not lead to treatment discontinuation. Understanding that these effects are diet-dependent gives patients control over their experience with the medication.
Very Common Side Effects
May affect more than 1 in 10 people
- Oily or fatty stools (steatorrhoea)
- Oily spotting on underwear
- Flatulence (gas) with oily discharge
- Urgent need to have a bowel movement
- Increased frequency of bowel movements
- Headache
Common Side Effects
May affect up to 1 in 10 people
- Abdominal pain or discomfort
- Faecal incontinence (loss of bowel control)
- Soft or liquid stools
- Bloating and flatulence
- Upper respiratory tract infection
- Irregular menstrual cycle
- Anxiety
Uncommon Side Effects
May affect up to 1 in 100 people
- Rectal pain or discomfort
- Tooth or gum disorders
- Fatigue
- Urinary tract infection
Rare Side Effects
May affect up to 1 in 1,000 people or fewer
- Allergic reactions (itching, rash, hives)
- Severe allergic reaction (anaphylaxis) – very rare
- Elevated liver enzymes
- Hepatitis (liver inflammation)
- Cholelithiasis (gallstones)
- Oxalate nephropathy (kidney damage)
- Pancreatitis
- Bullous eruptions (blistering skin rash)
Severe abdominal pain, yellowing of the skin or eyes (jaundice), dark urine, pale stools, persistent nausea or vomiting, or signs of a serious allergic reaction such as swelling of the face, lips, tongue, or throat, difficulty breathing, or severe skin rash. Although these events are rare, they require urgent medical evaluation. Stop taking Beacita and contact your doctor or go to the nearest emergency department immediately.
You are encouraged to report any suspected side effects to your healthcare provider or to your national pharmacovigilance authority. In the EU, side effects can be reported to the national competent authority in your country. In the UK, you can report side effects via the Yellow Card Scheme. Reporting side effects helps improve the safety information available for all patients taking this medication.
How Should You Store Beacita?
Store Beacita at room temperature below 25°C (77°F) in the original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiry date on the packaging.
Proper storage of Beacita ensures that the capsules remain effective throughout their shelf life. Store the capsules in their original blister packaging or container at a temperature not exceeding 25°C (77°F). Avoid storing them in humid environments such as bathrooms or kitchens near the stove, as moisture can degrade the capsules over time. Do not expose the medication to direct sunlight or excessive heat.
Keep Beacita and all medications out of the reach and sight of children. Although orlistat has low toxicity, accidental ingestion by children should be avoided. Store the medication in a secure location, ideally in a locked medicine cabinet or a high shelf that children cannot access.
Do not use Beacita after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month. If your capsules have expired, do not take them. Instead, return any unused or expired capsules to your pharmacy for safe disposal. Do not dispose of medications via household waste or wastewater, as pharmaceutical residues can contaminate the environment.
Return any unused or expired Beacita capsules to your local pharmacy for safe disposal. Many pharmacies participate in medication take-back programmes that ensure proper handling of pharmaceutical waste. Do not flush medications down the toilet or throw them in regular rubbish bins, as this can contribute to environmental contamination.
What Does Beacita Contain?
Each Beacita hard capsule contains 60 mg of orlistat as the active ingredient, along with inactive excipients including microcrystalline cellulose, sodium starch glycolate, povidone, sodium lauryl sulfate, and talc.
The active ingredient in each Beacita capsule is orlistat 60 mg. Orlistat is a semi-synthetic derivative of lipstatin, a natural product produced by the bacterium Streptomyces toxytricini. It is a potent and selective inhibitor of gastrointestinal lipases, the enzymes responsible for breaking down dietary triglycerides into absorbable free fatty acids and monoglycerides. By inhibiting these enzymes, orlistat prevents approximately 25% of ingested fat from being absorbed at the 60 mg dose.
The inactive ingredients (excipients) in Beacita serve various pharmaceutical functions. These typically include:
- Microcrystalline cellulose: A filler and binder that provides structure to the capsule contents
- Sodium starch glycolate: A disintegrant that helps the capsule contents break apart in the stomach for proper release of the active ingredient
- Povidone (polyvinylpyrrolidone): A binder that helps hold the powder mixture together
- Sodium lauryl sulfate: A surfactant that improves the wetting and dispersal of the capsule contents
- Talc: A glidant that improves the flow of powder during manufacturing
The hard capsule shell itself is typically composed of gelatin, titanium dioxide (E171), and possibly other colourants depending on the manufacturer and market. Patients with gelatin allergies should be aware that the capsule shell contains animal-derived gelatin. If you have dietary restrictions or allergies to any specific excipients, check the full list of ingredients on the product packaging or consult your pharmacist before use.
Beacita capsules should be swallowed whole. Do not open the capsules or mix the contents with food or drinks, as this could affect the medication's performance and may cause an unpleasant taste. The capsule shell is designed to dissolve in the stomach, releasing the orlistat powder to interact with dietary fat and lipase enzymes in the upper gastrointestinal tract.
Frequently Asked Questions About Beacita
Beacita is used for weight loss in overweight adults with a BMI of 28 or above. It contains orlistat 60 mg, which works by blocking the absorption of approximately 25% of the fat you eat. Beacita must be used alongside a reduced-calorie, lower-fat diet and is not intended as a standalone weight loss solution. It is available over the counter without a prescription in most European countries.
Take one Beacita 60 mg capsule three times daily — one with each of your three main meals. The capsule can be taken immediately before, during, or up to one hour after the meal. Swallow it whole with water. If your meal does not contain any fat, or if you skip a meal, do not take the capsule. Keep your fat intake to around 15 grams per meal to minimise gastrointestinal side effects.
If you forget to take your Beacita capsule within one hour of a meal, simply skip that dose and take your next capsule with your next main meal. Do not double up on doses to make up for a missed one. Taking extra capsules will not increase fat blocking but will increase the risk of gastrointestinal side effects. Occasional missed doses will not significantly affect your overall weight loss.
Yes, because Beacita reduces fat absorption, it can also reduce the absorption of fat-soluble vitamins A, D, E, and K. To compensate, take a daily multivitamin supplement containing these vitamins. For best absorption, take your multivitamin at bedtime or at least 2 hours before or after your Beacita dose. This helps ensure the orlistat does not interfere with vitamin uptake from the supplement.
Do not take Beacita for more than 6 months continuously without consulting a healthcare provider. If you have not lost weight after 12 weeks of consistent use alongside a reduced-calorie, lower-fat diet, consult a doctor or pharmacist. Some patients may benefit from longer-term use under medical supervision, but the OTC product is intended for self-directed treatment periods of up to 6 months.
Beacita and Alli both contain the same active ingredient (orlistat) at the same dose (60 mg) and are both available over the counter. They work identically. Xenical, on the other hand, contains a higher dose of orlistat (120 mg per capsule) and typically requires a prescription. The prescription-strength version blocks approximately one third of dietary fat, compared to one quarter for the 60 mg OTC versions. Your doctor can advise whether the OTC or prescription strength is more appropriate for your situation.
References and Sources
This article is based on internationally recognized medical and pharmaceutical guidelines. All information has been reviewed by qualified healthcare professionals and follows evidence-based principles.
- European Medicines Agency (EMA). Orlistat – Summary of Product Characteristics (SmPC). EMA, 2024. Available at: www.ema.europa.eu
- Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160–167.
- Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
- Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes. 2003;27(12):1437–1446.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization, 2023.
- British National Formulary (BNF). Orlistat. NICE, 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Orlistat (marketed as Alli and Xenical) Information. FDA, 2024. Available at: www.fda.gov
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, consisting of licensed physicians and specialists in clinical pharmacology with expertise in drug safety, pharmacovigilance, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and drug information. All content is researched and written using peer-reviewed sources and international pharmaceutical guidelines.
iMedic Medical Review Board – independent panel of qualified physicians who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, and WHO standards.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.